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Abstract
Background—Clostridium difficile infection (CDI) is public health threat and associated with 
significant mortality. However, there is a paucity of objectively derived CDI severity scoring 
systems to predict mortality.
Aims—To develop a novel CDI risk score to predict mortality entitled: Clostridium difficile 
Associated Risk of Death Score (CARDS).
Methods—We obtained data from the United States 2011 Nationwide Inpatient Sample (NIS) 
database. All CDI-associated hospitalizations were identified using discharge codes (ICD-9-CM, 
008.45). Multivariate logistic regression was utilized to identify independent predictors of 
mortality. CARDS was calculated by assigning a numeric weight to each parameter based on their 
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odds ratio in the final logistic model. Predictive properties of model discrimination were assessed 
using the c-statistic and validated in an independent sample using the 2010 NIS database.
Results—We identified 77,776 hospitalizations, yielding an estimate of 374,747 cases with an 
associated diagnosis of CDI in the United States, 8% of whom died in the hospital. The 8 severity 
score predictors were identified on multivariate analysis: age, cardiopulmonary disease, 
malignancy, diabetes, inflammatory bowel disease, acute renal failure, liver disease and ICU 
admission, with weights ranging from −1 (for diabetes) to 5 (for ICU admission). The overall risk 
score in the cohort ranged from 0 to 18. Mortality increased significantly as CARDS increased. 
CDI-associated mortality was 1.2% with a CARDS of 0 compared to 100% with CARDS of 18. 
The model performed equally well in our validation cohort.
Conclusion—CARDS is a promising simple severity score to predict mortality among those 
hospitalized with CDI.
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Introduction
Clostridium difficile infection (CDI) is the most common healthcare-associated infection in 
the United States.1 It is a major global public health threat 2–7 with mortality rates rapidly 
rising5 and the economic burden of CDI reported up to $4.8 billion annually in the United 
States alone.8–10
CDI therapies span the spectrum of efficacy and costs;11,12 however, CDI severity appears to 
be a key determinant of absolute and relative treatment efficacy.13 Expert-based 
classifications11 and to a lesser degree general comorbidity indexes (e.g. Horn Index) have 
been adopted into practice and CDI therapy studies.14 However, a robust, objectively derived 
CDI severity metric is lacking.15 Previously epidemiologic studies have either examined 
national patterns or derived clinical prediction tools from single institution cohorts.15 
Beyond the methodological concerns of these tools, linked to a lack of weighting variables, 
validation and calibration, data generated from these small cohorts suffer from limitations in 
generalizability.15 Additionally, single institution studies often fail to capture less prevalent 
conditions that have established strong associations with CDI-associated mortality, such as 
inflammatory bowel disease.15–18
Large administrative databases offer a number of advantages including generalizability over 
a broad population and a large sample size facilitating adequate power to examine exposures 
and outcomes.19 However, most diseases studied in administrative databases are not risk 
adjusted for disease severity.20 Development and validation of CDI severity scores in 
administrative database will allow estimation of CDI trends in disease outcomes stratified by 
severity, and facilitate comparisons of severity across populations. Accordingly, a robust 
CDI severity metric will deepen our understanding of CDI population-based trends, and aid 
in determining if temporal changes in outcomes are uniform across all CDI or limited to 
those with milder disease, an unmet need.21
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Accordingly, given the paucity of a robust severity scoring system to predict CDI-associated 
inhospital mortality, our study aimed to develop and validate an objectively derived severity 
score to predict CDI-associated mortality using a large administrative database.
Methods
Data Source and Study Population
The data source for our study was the United States 2011 Nationwide Inpatient Sample 
(NIS), the largest source of all-payer hospital discharge information in the United States. 
The NIS retrospectively contains all discharge data from a 20% stratified sample of 
community hospitals. The 2011 NIS captures data from 1,049 hospitals within 46 states, 
accounting for 8,023,590 hospital discharges.22 Each individual hospitalization is treated as 
its own entry and coded with a single primary diagnosis, up to 24 secondary diagnoses and 
as many as 15 procedure-associated codes derived from the International Classification of 
Disease, 9th Edition, clinical modification (ICD-9-CM). Our target population consisted of 
patients with a primary or secondary discharge diagnosis of CDI (ICD-9-CM 008.45, 
n=77,776, which estimates a total of 374,747 CDI hospitalizations in the United States). The 
ICD-9 code for CDI has been validated and is widely used to estimate healthcare burden due 
to this disease.23,24
Definition of Outcomes and Variables of Interest
The primary outcome of interest was in-hospital mortality among patients with CDI, which 
was directly obtained from the NIS dataset. Demographic variables of age, gender, race, 
insurance status, and median income quartile per zip code were ascertained from the NIS 
database. Missing data from age (n=9), gender (n=9), and mortality status (n=142) were 
excluded. “Native American” and “Other Race” were combined given the small numbers. To 
facilitate a practical, simple severity score, age was categorized into 4 strata: 18–40 years, 
41–60 years, 61–80 years, 81–100 years. Comorbidity burden was examined utilizing the 
validated and widely used Charlson comorbidity index, which consists of 17 distinct 
conditions, with a higher composite score representing greater comorbidity.25 Previously 
validated coding algorithms for defining Charlson comorbidities using ICD-9 administrative 
data was utilized.26 Meaningful Charlson comorbidity categories were grouped to facilitate 
ease of use (Supplemental Material eTable 1). Briefly, the categories included: 1) 
cardiopulmonary disease (myocardial infarction, congestive heart failure, peripheral vascular 
disease, cerebrovascular disease, chronic obstructive pulmonary disease), 2) hepatic disease 
(mild, moderate or severe liver disease), 3) diabetes (diabetes with or without chronic 
complications), 4) malignancy (metastatic solid tumors and malignancy including 
lymphoma/leukemia but excluding benign skin cancer). In addition to these potential 
predictors and demographics, a number of other possible predictor variables were assessed a 
priori based on a literature review, including acute renal failure, inflammatory bowel 
disease, rheumatic arthritis, hemiplegia/paraplegia, peptic ulcer disease, and HIV/AIDS, 
with corresponding ICD-9 codes contained in Supplemental Material (eTable 1). Intensive 
care unit (ICU) admission is a significant predictor of mortality and accordingly a surrogate 
variable was synthesized as this data element is not embedded in the NIS dataset. An ICU 
admission was defined by identification of any of the following procedure codes: continuous 
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invasive mechanical ventilation for 96 consecutive hours or more, or of unspecified duration 
(ICD-9, 96.72, 96.70), arterial catherization (38.91), systemic arterial pressure monitoring 
(89.61), or central venous pressure monitoring (89.62). Each of these procedures are 
traditionally performed only in high-monitoring care units, thus have high specificity as 
surrogates for ICU admission.
Statistical Analysis
Data were analyzed utilizing Stata 13.0 (StataCorp, College Station, TX). The Stata svy 
survey estimation command was used to account for the NIS stratified sampling technique 
for nationwide estimates. Continuous variables were summarized using means and standard 
deviations and compared using a t-test. Categorical variables were summarized using 
proportions and compared using the chi-square test. Using a priori predictors, a stepwise 
multivariate logistic regression with backward elimination was performed to identify 
independent predictors of mortality, with a p-value threshold of 0.05 for retention in the 
model. Next, using the significant predictors generated for the above logistic regression, a 
multivariate logistic regression model was developed. The risk score (CARDS) was 
constructed assigning weights for each individual predictive variable corresponding to the 
odds ratio, rounded to nearest whole number. The cumulative severity score was calculated 
by adding the weighted, rounded values for each independent predictor variable. The 
discriminative ability of the severity score was assessed using c-statistic and performance 
compared to age, gender, Charlson co-morbidity index, with and without ICU admission. 
The c-statistic ranges from 0.5 to 1.0, with 1.0 indicating perfect discrimination and 0.5 
indicating no ability to discriminate.
Validation of the severity score
The severity score was validated in an independent cohort of all CDI hospitalizations using 
the 2010 NIS database (n=67,715, which estimates a total of 335,963 CDI hospitalizations in 
the United States). All variable manipulation and statistical tests were performed identical to 
the initial analysis. The performance of the CARDS score in the validation cohort was 
compared by assessing mortality associated with specific values of the severity score as well 
as comparing the overall performance of the model using a c-statistic.
IRB approval was not required at our institution as the NIS is a publically available de-
identified database.
Results
Study Population
We identified 77,776 CDI hospitalizations in the NIS 2011 dataset, translating to an estimate 
of 374,747 CDI cases in the United States, of which 8% were associated with in-hospital 
mortality. The total study population had a mean age of 69 years (standard deviation (SD) 17 
years) with 59% females (45,595) and 41% males (32,181). Whites were the most common 
race, comprising 68% of the cohort with Blacks and Hispanics comprising 12% and 7% 
respectively. As expected given the older age of our sample, Medicare, as captured within 
NIS, was the predominant insurance type accounting for 54,456 hospitalizations (70%). The 
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mean Charlson comorbidity index was 2.31 (SD 2.22) and the mean length of stay 11.57 
days (SD 14.48). Table 1 presents demographic and clinical data from patients in hospital 
with CDI stratified by in-hospital mortality. Patients with a CDI who died in hospital were 
older and had more comorbidities (mean Charlson comorbidity index 3.01 versus 2.25, 
p<0.001). Both groups had the majority of hospitalizations occur in females, Whites and 
with Medicare insurance. There were no significant differences among median income per 
zip code in either group (Table 1).
Predictors of CDI-associated mortality
The multivariate analysis of predictors of CDI-associated in-hospital mortality is highlighted 
in Table 2. A progressive increase in age was associated with greater odds of CDI-associated 
mortality, particularly patients between 81–100 years (OR 4.12, 95% CI: 3.39–4.99) 
compared adults between 18–40 years. ICU admission and acute renal failure were among 
the strongest predictors of CDI-associated mortality with a five-fold (OR 5.29, 95% CI: 
4.85–5.77) and threefold increase in mortality (OR 2.93, 95% CI: 2.76–3.13), respectively. 
Chronic conditions were also independent predictors of CDI-associated mortality including 
liver disease (OR 2.00, 95% CI: 1.78–2.25), malignancy (OR 1.89, 95% CI: 1.74–2.05), 
inflammatory bowel disease (OR 1.72, 95% CI: 1.49–1.99) and cardiopulmonary disease 
(OR 1.46, 95% CI: 1.38–1.56). Diabetes was associated with decreased odds of CDI-
associated mortality in multivariate analysis (OR 0.83, 95% CI: 0.77–0.88).
Development and Performance of CARDS
Table 3 presents the weights of the individual components of the severity score. Patients 
between 81–100 years, 61–80 years, 41–60 years, and 18–40 years received 4 points, 3 
points, 2 points and 0 points, respectively. Patients admitted to the ICU/critical care ward 
received 5 points, and those with acute renal failure received 3 points. Patients with liver 
disease (mild, moderate or severe), inflammatory bowel disease (Crohn’s disease or 
ulcerative colitis), or malignancy with or without metastatic disease received 2 points for 
presence of any of these three conditions (maximum 6 points). Patients also received a 
maximum of 1 point if they have any of cardiopulmonary diseases previously defined. 
Patients with diabetes with or without chronic complications receive −1 points, subtracting a 
point from their cumulative CARDS. Therefore, the possible CARDS ranged from −1 to 19, 
with a maximum total CARDS of 18 in our dataset (Figure 1). Mortality increased 
significantly as CARDS increased. This ranged from 1.2% CDI-associated mortality with a 
CARDS of 0 to 100% CDI-associated mortality with CARDS of 18 (Table 4). CARDS 
performed well in terms of model discrimination compared to existing models. CARDS had 
a c-statistic of 0.77 whereas a standard model of age, gender, Charlson comorbidity index, 
and ICU admission only had a c-statistic of 0.73. CARDS also outperformed a model of age, 
gender, Charlson comorbidity index alone, which had a c-statistic of 0.63 (Supplemental 
Material eFigure 1).
Validation of CARDS
The performance of CARDS was validated in an independent sample of all CDI 
hospitalizations from the 2010 NIS dataset. Similar to the derivation cohort, the validation 
cohort had a maximum total CARDS was 18, with mortality increasing as CARDS 
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increased. This ranged from 0.3% CDI-associated mortality with a CARDS of 0 to 100% 
CDI-associated mortality with CARDS of 18 (Table 4). Importantly, the severity scoring 
system had a comparable performance with a c-statistic of 0.77.
Discussion
Clostridium difficile infection is a major public health threat with significant associated 
mortality, supported by this study, which reports an 8% CDI-associated mortality rate among 
hospitalized patients in the United States. Despite the impact of CDI, there is an absence of a 
robust CDI severity scoring system. Accordingly, we developed the Clostridium difficile 
Associated Risk of Death Score (CARDS), an objectively derived severity score to predict 
CDI-associated mortality.
Our study highlights that several predictive risk factors and the CARDS model displays 
good discriminative ability, which was validated in an independent CDI cohort. Age has 
been identified has a risk factor of initial CDI development and CDI-associated mortality.11 
A recent systematic review27 highlights advanced age as an independent predictor of CDI-
associated mortality with estimates ranging from risk ratio (RR) 1.41 (95% CI: 1.1–1.81)28 
in those between 75–84 years to as high as OR 6.5 (95% CI: 1.7–24.3) in those ≥75 years.29 
Interestingly, data from the 2007 NIS dataset supports the progressive increase odds of CDI-
associated death with increasing age, although estimates were modest particularly at the 
most advanced ages. Stewart and Hollenbeak30 reported ORs of 2.45 (95% CI: 2.31–2.61) 
and 1.81 (1.71–1.92) for CDI-associated mortality in patients over 70 years and between 51–
70 years, respectively, compared to their young adult reference. In our study, ICU admission 
was also a strong independent predictor of CDI-associated mortality (OR 5.23, 95% CI: 
4.79–5.72). This is in keeping with data from a small, observational cohort that suggests 
septic shock, ward-to-ICU transfer, and increased APACHE scores as significant 
independent predictors of 30-day mortality.31 A number of chronic comorbidities are 
important predictors of CDI-associated mortality. Inflammatory bowel disease, malignancy 
and liver disease were all independently identified to increase the odds of CDI-associated 
death in our model. Our results are consistent with emerging literature that highlights the 
deleterious consequences of these comorbidities when linked to CDI.17,32,33
There is a paucity of data examining the relationship between diabetes mellitus and CDI. In 
a small study, diabetes mellitus has been identified as a risk factor for recurrence of CDI34; 
however, to our knowledge, our study is the first to demonstrate that diabetes was associated 
with decreased odds of CDI-associated mortality (OR 0.83, 95% CI: 0.77–0.88). 
Interestingly, this association become stronger on multivariate analysis compared to 
uncontrolled, univariate analysis, which does not support the hypothesis that the diabetes 
effect is likely because of adjustment for other co-morbidity and may not be specific to 
diabetes. We offer two possible explanations for this relationship. First, Viladominu and 
colleagues35 demonstrated that CDI-infected mice treated with pioglitazone, a common anti-
diabetic medication, ameliorated colitis through the peroxisome proliferator-activation 
receptor pathway. If a similar inverse association between thiazolidinedione use and severity 
of CDI exists in humans, this reduction in severity in users may explain the inverse 
association observed between diabetes and mortality in CDI patients. This hypothesis merits 
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further evaluation in cohorts with data on medication use. Second, diabetic patients are 
likely to have had more statin use, which has been shown to have a dose-response protective 
effect on mortality in patients with CDI.36 Overall, as the the relationship between diabetes 
mellitus and CDI has been reported to be protective37 and associated with mortality38, 
further studies exploring the mechanisms behind this are warranted.
For clinicians, CARDS may hold promise to stratify severity among similarly presenting 
CDI cases, guiding which patients may benefit from early expensive treatments such as 
fidaxomicin or vancomycin, closer follow-up, or both. This is particularly important given 
the CDI outcomes among IBD patients39–42 and the rise of community acquired CDI.43 
Additionally, CARDS may be useful in CDI therapy clinical trials, in order, to better account 
for severity driving outcomes. A recent systematic review of CDI complication prediction 
scores concluded current tools are ‘suboptimal’ and of ‘debatable utility’ given 
methodological limitations including a lack of validation, performance and issues rooted in a 
small sample size.15 Although there may be other factors that drive disease severity that are 
not captured in administrative databases, CARDS may have clinical utility serving as a 
framework over which other established laboratory and medication factors may be overlaid 
to leverage a more comprehensive CDI severity metric, given its validation, robust c-statistic 
and derivations from 71,357 CDI hospitalizations.
For epidemiologists, given that CARDS is grounded in a national database, it offers utility in 
adjustment for disease severity in research using administrative data, enabling meaningful 
comparisons between populations and over time. Additionally, this severity score helps 
highlight an unmet need, if improvements in mortality are only identified in specific severity 
strata, for example those with mild disease. Such effects have been seen in secular trends for 
other diseases such as inflammatory bowel disease where the development of severity score 
using administrative data allowed one to define that reduction in colectomy rates were seen 
only in those with mild or moderate severity of hospitalizations with no differences in rates 
over the past decade in those with the most severe disease. Lastly, CARDS may seamlessly 
be adapted into a quality improvement metric for which public health officials and hospital 
administrators can monitor the burden of CDI in individual hospitals. If severity scores are 
persistently elevated it may signal to stakeholders that selected NAP-1/027 testing might be 
required or other exploration should be undertaken.
This study does have a few limitations. The absence of clinical and treatment data, such as 
the use of antibiotics, thiazolidinedione or proton pump inhibitor medications are salient 
limitations. Also, the United States NIS is a discharge abstract database whereby repeat 
admissions for recurrent CDI cannot be differentiated. Individual-level clinical data are not 
traditionally available in large administrative databases that capture the national burden of 
disease. The absence of laboratory investigations (e.g. white blood cell count) that have been 
previously described as associated with mortality, is a relevant limitation; however, this data 
is not commonly available in large administrative database.23 Efforts were made to generate 
a surrogate marker for elevated creatinine, another salient laboratory parameter, in the model 
by using the acute renal failure diagnostic code. Additionally, physiological parameters and 
laboratory investigations change rapidly, so it is difficult to ascertain which is the relevant 
measurement, in turn reducing the consistency of scoring among observers. While we 
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modeled for the presence of several co-morbidities, it is possible that the severity of such co-
morbid illnesses could additionally influence outcome and we were not able to completely 
adjust for this. We were unable to directly ascertain ICU-level care and used surrogates of 
mechanical ventilation or hemodynamic monitoring. We acknowledge that this assumption 
may underestimate the number of C difficile patients care for in an ICU-setting. However, 
given the wide variability between institutions in the threshold for ICU-care, we elected to 
choose markers that would retain high specificity for this covariate. We were also unable to 
control or delineate fatal adverse events related to CDI-specific treatments. 
Methodologically, non-linear relationships may exist and merit exploration in future studies. 
Despite the absence of clinical, laboratory and treatment data, given the widespread use and 
familiarity of diagnosis and procedure codes, CARDS offers a simple, robust and practical 
tool. Future studies building upon CARDS should aim to include laboratory investigations 
and microbial markers such as ribotype though such markers as the NAP-1/027 ribotype 
have not been consistently associated with more severe disease.
In conclusion, to our knowledge, CARDS is the first objectively derived severity score to 
predict CDI-associated mortality using a national administrative database. Although 
validation in other cohorts is needed, this simple severity improves generalizability and is a 
promising tool for epidemiologists and clinicians.
Supplementary Material
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Figure 1. 
CARDS distribution and percent mortality by score among patients hospitalized with 
Clostridium difficile infection. Among the United States 2011 Nationwide Inpatient Sample, 
CARDS totals formed a normal distribution, and the possible CARDS total ranged from −1 
to 19, with a maximum total CARDS of 18 in the dataset. Clostridium difficile infection-
associated mortality increased significantly as CARDS total increased.
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Table 1
Summary of demographic data of hospitalized patients with Clostridium difficile infection who had fatal event 
compared to those who survived among the United States Nationwide Inpatient Sample*
Demographic Characteristics
CDI-associated mortality cohort (n 
=6,168)
CDI-associated survivor cohort (n = 
71,608) p-value
Age categories - N (%) p<0.001
 18 – 40 years 142 (2) 5,353 (7)
 41– 60 years 793 (13) 14,969 (21)
 61 – 80 years 2,736 (44) 30,464 (43)
 81 – 100 years 2,497 (41) 20,822 (29)
Gender - N (%) p< 0.001
 Female 3,344 (54) 42,251 (59)
 Male 2,824 (46) 29,357 (41)
Race - N (%) p<0.001
 White 4,144 (67) 48,894 (68)
 Black 782 (13) 8,415 (12)
 Hispanic 487 (8) 5,094 (7)
 Asian/Pacific Islander 136 (2) 1,144 (12)
 Other Race 188 (3) 1,966 (3)
 No Race Reported 431 (7) 6,095 (9)
Mean Length of Stay 15.35 (21.85) 11.24 (13.62) p<0.001
Insurance Source - N (%) p<0.001
 Medicare 4,726 (77) 49,730 (70)
 Medicaid 418 (7) 6,172 (9)
 Private 788 (13) 12,798 (17)
 Other 219 (4) 3,064 (4)
Median income quartile per zip code - N (%) p=0.316
 1 1,550 (26) 18,097 (26)
 2 1,416 (23) 16,718 (23)
 3 1,572 (26) 18,567 (26)
 4 1,521 (25) 16,898 (24)
Charlson comorbidity index - mean (SE) 3.01 (2.44) 2.25 (2.19) P<0.001
*Unweighted United States 2011 NIS hospitalization data
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Table 2
Multivariate analysis of predictors of CDI-associated mortality.* Eight significant severity score predictors 
were identified. ICU admission, age and acute renal failure were strong predictors of mortality whereas liver 
disease, malignancy, inflammatory bowel disease and cardiopulmonary disease were moderate predictors of 
mortality. Diabetes had a modest protective impact on CDI-associated mortality.
Characteristic Odds ratio 95% Confidence interval
Age
 18 – 40 years Reference
 41 – 60 years 1.51 1.24–1.82
 61 – 80 years 2.51 2.06–3.06
 81 – 100 years 4.12 3.39–4.99
ICU admission
 No Reference
 Yes 5.29 4.85–5.77
Acute renal failure
 No Reference
 Yes 2.93 2.76–3.13
Liver disease
 No Reference
 Yes 2.00 1.78 – 2.25
Malignancy (with or without metastatic disease)
 No Reference
 Yes 1.89 1.74 – 2.05
Inflammatory bowel disease
 No Reference
 Yes 1.72 1.49 – 1.99
Cardiopulmonary disease
 No Reference
 Yes 1.46 1.38–1.56
Diabetes (with or without complications)
 No Reference
 Yes 0.83 0.77 – 0.88
*Survey weighted United States 2011 NIS hospitalization data
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Table 3
Summary of Clostridium difficile Associated Risk of Death Score (CARDS) to predict mortality among 
hospitalized patients with Clostridium difficile infection. Points are summated for each CARDS predictor that 
a hospitalized patient with Clostridium diffcile infection posses, in turn, yielding a CARDS total associated 
with a mortality rate. The CARDS total range is between −1 to 19.
Predictors Points
Critical care/ICU admission 5
Age
 18 – 40 years 0
 41 – 60 years 2
 61 – 80 years 3
 81 – 100 years 4
Renal failure (acute) 3
Diabetes −1
Serious comorbidities
 Cardiopulmonary disease 1
 Liver disease 2
 Inflammatory bowel disease 2
 Malignancy 2
CARDS Total −1 to 19
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Table 4
CARDS total and predicted CDI-associated mortality rate. Mortality increased significantly as CARDS total 
increased. Clostridium difficile infection-associated mortality was 1.2% with a CARDS of 0 compared to 
100% with CARDS of 18 among the United States 2011 Nationwide Inpatient Sample (NIS). A similar 
prediction was demonstrated in an external validation cohort, United States NIS 2010 dataset.
CARDS Total Mortality (NIS 2011) Mortality (NIS 2010)
0 1.15% 0.33%
5 4.4% 4.5%
10 20.8% 23.3%
15 48.1% 49.7%
18 100.00% 100.0%
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